Jul 23,2019

New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today the publication of a peer-reviewed paper demonstrating that Remote Electrical Neuromodulation (REN) is as effective as acute pharmacological treatments in treating the symptoms of migraine. The article, published in The Journal of Headache and Pain, compared the efficacy of Theranica's Nerivio™ REN device to previous acute care in the same patients. The post-hoc analysis used data from a randomized, double-blind, sham-controlled pivotal study in adult migraine patients.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 20,2019

People With Diabetes Using One Drop & Afrezza Significantly Lower A1c In 3 Months

In a partnership between One Drop and Mannkind, the A-One randomized control trial was conducted to evaluate inhalable insulin and digital therapy among people with type 2 diabetes. Participants were randomized to receive One Drop + Afrezza, or One Drop + their current injectable bolus insulin. All enrolled participants used One Drop's solution for 3 months and people in the One Drop + Afrezza group received a 3-month supply of Afrezza upon receipt of a prescription. Results showed that people with type 2 diabetes using One Drop's integrated digital diabetes care platform with Afrezza inhaled insulin improve their A1c by an absolute -0.93%.

CLINICAL STUDY

#mobile app

#connected device

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 22,2019

Propeller Health: 84% of People with Asthma May Be Using Their Inhaler Incorrectly

The vast majority of people with asthma may be using their inhalers incorrectly, potentially making their medicine less effective and increasing their risk of asthma attacks, according to new research published in The Journal of Allergy and Clinical Immunology. Traditionally, asthma medicines require that patients take two “puffs” of their inhaler to receive the prescribed dose.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 27,2019

New Study Signals Benefits of Digital Therapy for Stroke Patients

The Learning Corp, a next generation digital therapeutics company, has published the first large scale retrospective study of post-stroke rehabilitation practices that compares outcomes among patients using tablet-based therapy at home and those who complete the same therapy in a clinic. The study, published in Frontiers in Neurology, analyzed data from 3,686 Constant Therapy users—patients with post-stroke aphasia—over a four year period (2013-2017). The study’s findings are relevant to the more than seven million people in the United States who are living post-stroke and the approximately 2.5 million people living with aphasia due to stroke.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 10,2019

Study: Behavioral coaching app reduces hypertensive participants' blood pressure

The investigation examined Better Therapeutics’ candidate digital therapeutic for cardiovascular disease, a daily-use app that encourages users to set and record their progress toward individualized behavioral goals. The app is supported by a remote multidisciplinary team that looks to support healthy behavior changes, with users receiving scheduled calls from a health coach over the course of a 12-week program. Among 172 participants with hypertension, 75 percent achieved a “clinically meaningful” improvement in blood pressure. The group was 86 percent women and the mean age in the sample was 55.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
May 08,2019

Study: Kaia Health's back pain app outperforms standard therapy, online education

A randomized controlled trial recently published in npj Digital Medicine found Kaia Health’s app-based exercise therapy for lower back pain (LBP) to be an effective treatment for multidisciplinary patients, and could be more effective than a standard strategy of individual physiotherapy sessions paired with online education.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 20,2019

3 New Insights About COPD From Propeller’s Digital Health Tools

This week at ATS 2019, Propeller Health presented three new findings on COPD, all of which used digital health tools to monitor patients’ medication use in a real-world setting and reveal new insights about their disease. This is the latest research to demonstrate how digital health tools continue to revolutionize the way we treat respiratory disease. When providers and patients can monitor the patient’s daily medication use, they’re more likely to adhere to their maintenance medication regimen and thereby experience fewer symptoms and require emergency treatment less often.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 30,2019

CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App

Results from the world’s first randomized control study to examine digital therapeutic smoking cessation programs were presented on May 20th at the American Thoracic Society International Conference. Total of 572 patient data was used for analysis. The main evaluation item is "Continuous Abstinence Rate (CAR) at Week 9-24". The findings demonstrate that CureApp’s nicotine dependence treatment app resulted in an improvement in continuous abstinence rate (CAR) compared to a control group over multiple time points.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 11,2019

DarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association's 79th Scientific Sessions

DarioHealth Corp. (NASDAQ: DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Association's (ADA) 79th Scientific Sessions in San Francisco, California. The results of the studies highlight that for 4,917 T2D users measuring more than 15 times per month, the average of % in-range readings (70-140 mg/dL) was increased in correlation to app engagement (occurrences of tagging meals, carbs, physical activity).

CLINICAL STUDY

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 12,2019

Study: Combination of self-monitoring blood glucose device & DTx improve patient outcomes

At the 79th Annual Scientific Sessions of the American Diabetes Association in San Francisco, pharma giant Roche and India-based digital therapeutics company Wellthy Therapeutics presented real world data of improved diabetes care outcomes in a South Asian population when patients followed prescribed plan of medication and lifestyle modification in conjunction with a combination therapy of self-monitoring blood glucose device and a clinically validated digital therapeutic (DTx). The study evaluated data from 833 individuals who used both the Accu-Chek Active blood glucose monitor and the Wellthy Care Digital Therapeutic, to form an iPDM (integrated personalised diabetes management) solution. The study demonstrated that increased engagement on the combined Digital Therapeutic (DTx) was highly correlated with reduced blood sugar levels from baseline.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY